The Peruvian Ministry of Health’s Directorate General of Medicines, Supplies, and Drugs (Digemid) has initiated a robust training program aimed at enhancing the skills of pharmacists responsible for dispensing and regulating Fentanyl across the country.
In a strategic move to curb the rising threats associated with Fentanyl misuse, Digemid conducted three comprehensive training sessions. These sessions targeted over 120 pharmaceutical chemists and regulatory personnel from various regions, including inspectors from Integrated Health Network Directors and Regional Health Management teams. The program also involved specialists from 16 hospitals and representatives from pharmaceutical importers and manufacturers.
Collaborative Training Efforts
The training, a joint effort between Digemid and the Ministry of the Interior’s General Intelligence Directorate, focused on regional Fentanyl challenges, legal aspects, and effective control measures. Participants engaged in discussions about theft reports handled by the National Police and shared best practices for prescription and oversight. The initiative emphasized the importance of coordinated actions to prevent the diversion of Fentanyl for illicit purposes.
Enhancing Public Health Safeguards
Janireth Pahuara, head of Digemid’s Controlled Products Team, highlighted the program’s goal to implement preventive mechanisms that protect public health. By reinforcing proper usage protocols in hospitals and conducting medical audits, the program seeks to minimize the risk of addiction and mortality linked to Fentanyl. Pahuara stressed that a unified approach across various sectors is crucial to maintaining control over this potent medication.
• Strengthened surveillance and control mechanisms for Fentanyl
• Enhanced collaboration between health and law enforcement agencies
• Implementation of strict prescription and dispensing protocols
• Increased awareness about the risks of Fentanyl misuse
The training sessions have laid the groundwork for a more vigilant and informed pharmaceutical community. By equipping pharmacists and regulatory authorities with the necessary tools and knowledge, Digemid aims to create a resilient defense against the misuse of Fentanyl. This proactive approach not only addresses current challenges but also prepares the healthcare system for future threats related to controlled substances.
Effective management of Fentanyl is critical in safeguarding public health. The comprehensive training provided by Digemid ensures that pharmacists are well-prepared to handle the complexities associated with this powerful drug. By fostering a culture of responsibility and accountability, Digemid contributes to a safer healthcare environment and mitigates the risks posed by potential misuse.
Ultimately, Digemid’s efforts to empower pharmacists reflect a deep commitment to public health and safety. The agency’s strategic initiatives demonstrate a forward-thinking approach to pharmaceutical regulation, ensuring that essential medications are used appropriately while preventing their exploitation for harmful purposes.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
